KSKevin M. Shannon

Kevin M. Shannon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin M. Shannon has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Michelle M. Le Beau

    From the Department of Pediatrics, University of California, San Francisco, California; the Department of Laboratory Medicine, University of California, San Francisco, California; University of Texas Southwestern, Dallas, Texas; Section of Hematology/Oncology, Department of Medicine, and The Cancer Research Center, University of Chicago, Chicago, Illinois

    5 shared publications
  • Brigit R. Taylor

    From the Departments of Pediatrics and Medicine, Gladstone Institute of Cardiovascular Disease, and Cardiovascular Research Institute, University of California, San Francisco (UCSF), CA

    4 shared publications
  • Mary Gratiot

    From the Department of Pediatrics, University of California, San Francisco, CA; Department of Cancer Research; Merck and Co, West Point, PA; and Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA

    3 shared publications
  • Nidal Mahgoub

    Department of Pediatrics, University of California, San Francisco, CA, USA

    3 shared publications
  • Scott C. Kogan

    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California 94143

    3 shared publications
  • Tyler Jacks

    From the Department of Pediatrics, University of California, San Francisco, CA; Department of Cancer Research; Merck and Co, West Point, PA; and Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA

    3 shared publications

Latest Publications

  • Therapy-induced malignant neoplasms in Nf1 mutant mice

    by Richard C. Chao, Urszula Pyzel, Jane Fridlyand, Yien-Ming Kuo, Lewis Teel, Jennifer Haaga, Alexander Borowsky, Andrew Horvai, Scott C. Kogan, Jeannette Bonifas, et al.


  • Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells

    by Suzanne Schubbert, Kenneth Lieuw, Sara L. Rowe, Connie M. Lee, XiaXin Li, Mignon L. Loh, D. Wade Clapp, Kevin M. Shannon

    PTPN11 encodes the protein tyrosine phosphatase SHP-2, which relays signals from growth factor receptors to Ras and other effectors. Germline PTPN11 mutations underlie about 50% of Noonan syndrome (NS), a developmental disorder that is associated with an elevated risk of juvenile myelomonocytic leukemia (JMML). Somatic PTPN11 mutations were recently identified in about 35% of patients with JMML; these mutations introduce amino acid substitutions that are largely distinct from those found in NS. We assessed the functional consequences of leukemia-associated PTPN11 mutations in murine hematopoietic cells. Expressing an E76K SHP-2 protein induced a hypersensitive pattern of granulocyte-macrophage colony-forming unit (CFU-GM) colony growth in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) that was dependent on SHP-2 catalytic activity. E76K SHP-2 expression also enhanced the growth of immature progenitor cells with high replating potential, perturbed erythroid growth, and impaired normal differentiation in liquid cultures. In addition, leukemia-associated SHP-2 mutations conferred a stronger phenotype than a germline mutation found in patients with NS. Mutant SHP-2 proteins induce aberrant growth in multiple hematopoietic compartments, which supports a primary role of hyperactive Ras in the pathogenesis of JMML.


  • JAKing up hematopoietic proliferation

    by Kevin Shannon, Richard A. Van Etten


  • Open Access

    Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells

    by Tamiko R. Katsumoto, Jennifer Duda, Andrew Kim, Zabihullah Wardak, Glenn Dranoff, D. Wade Clapp, Kevin Shannon

    Granulocyte/macrophage colony-stimulating factor (GM-CSF) promotes the survival, proliferation, and differentiation of myeloid lineage cells and regulates chemotaxis and adhesion. However, mice in which the genes encoding GM-CSF (Gmcsf) or the β common subunit of the GM-CSF receptor (βc) are inactivated display normal steady-state hematopoiesis. Here, we show that host GM-CSF signaling strongly modulates the ability of donor hematopoietic cells to radioprotect lethally irradiated mice. Although bone marrow mononuclear cells efficiently rescue Gmcsf mutant recipients, fetal liver cells and Sca1+ lin−/dim marrow cells are markedly impaired. This defect is partially attributable to accessory cells that are more prevalent in bone marrow. In contrast, Gmcsf-deficient hematopoietic stem cells demonstrate normal proliferative potentials. Short-term survival is also impaired in irradiated βc mutant recipients transplanted with fetal liver or bone marrow. These data demonstrate a nonredundant function of GM-CSF in radioprotection by donor hematopoietic cells that may prove relevant in clinical transplantation.


  • Open Access

    Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

    by Doan T. Le, Namie Kong, Yuan Zhu, Jennifer O. Lauchle, Abigail Aiyigari, Benjamin S. Braun, Endi Wang, Scott C. Kogan, Michelle M. Le Beau, Luis Parada, et al.

    The NF1 tumor suppressor gene encodes a guanosine triphosphotase (GTPase)-activating protein that negatively regulates Ras signaling and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs). Adoptive transfer of fetal liver cells from Nf1 mutant mice models JMML; however, this system has important limitations as a platform for performing biologic and preclinical studies. We have exploited the interferon-inducible Mx1-Cre transgene to ablate a conditional mutant Nf1 allele in hematopoietic cells. Somatic inactivation of Nf1 induces a myeloproliferative disorder with 100% penetrance that is associated with a sub-acute clinical course, tissue infiltration by myeloid cells, hypersensitivity to granulocyte-macrophage colony stimulating factor, hyperproliferation, and resistance to apoptosis. These Mx1-Cre, Nf1flox/flox mice establish a tractable experimental model for testing therapeutics and for identifying mutations that cooperate with hyperactive Ras in myeloid leukemogenesis. (Blood. 2004;103:4243-4250)


  • The sum is greater than the FGFR1 partner

    by Benjamin S Braun, Kevin Shannon


  • RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7

    by Lucy E. Side, Nicole P. Curtiss, Kathryn Teel, Christian Kratz, Pauline W. Wang, Richard A. Larson, Michelle M. Le Beau, Kevin M. Shannon

    Oncogenic mutations in the KRAS2, NRAS, or FLT3 gene are detected in more than 50% of patients with de novo acute myeloid leukemia (AML). RAS mutations are also prevalent in de novo myelodysplastic syndrome (MDS), especially chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. However, few studies have examined these genetic lesions in therapy-related myeloid malignancies. Monosomy 7/del(7q) and monosomy 5/del(5q) represent the most common cytogenetic abnormalities in therapy-related MDS and AML (t-MDS/t-AML) and are strongly associated with prior exposure to alkylating agents. Mutational analysis of bone marrow specimens from a well-characterized cohort of 26 t-MDS/t-AML patients with abnormalities of chromosomes 5 and/or 7 revealed 3 with RAS mutations. Further analyses of 23 of these cases uncovered one FLT3 internal tandem duplication and five TP53 mutations. The four patients with RAS or FLT3 mutations had monosomy 7, including one with abnormalities of chromosomes 5 and 7. One specimen demonstrated mutations in both KRAS2 and TP53. RAS and FLT3 mutations, which are thought to stimulate the proliferation of leukemia cells, appear to be less common in t-MDS/t-AML than in de novo AML, whereas TP53 mutations are more frequent.


  • Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder

    by Benjamin S. Braun, David A. Tuveson, Namie Kong, Doan T. Le, Scott C. Kogan, Jacob Rozmus, Michelle M. Le Beau, Tyler E. Jacks, Kevin M. Shannon

    RAS mutations are common in myeloid malignancies; however, it is not known whether oncogenic RAS can initiate leukemia. We show that expressing mutant K-Ras G12D protein from the endogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance characterized by tissue infiltration, hypersensitivity to growth factors, and hyperproliferation. Hematopoietic cells from diseased mice demonstrated increased levels of Ras-GTP, but effector kinases were not constitutively phosphorylated and responded normally to growth factors. Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies.


  • Open Access

    Hematologic effects of inactivating the Ras processing enzymeRce1

    by Abigail L. Aiyagari, Brigit R. Taylor, Vikas Aurora, Stephen G. Young, Kevin M. Shannon

    Posttranslational processing of Ras proteins has attracted considerable interest as a potential target for anticancer drug discovery. Rce1 encodes an endoprotease that facilitates membrane targeting of Ras and other prenylated proteins by releasing the carboxyl-terminal 3 amino acids (ie, the -AAX of the CAAX motif). Homozygous Rce1 mutant embryos(Rce1−/−) die late in gestation. To characterize the role of Rce1 in hematopoiesis, we performed adoptive transfers and investigated cells from the recipients. Rce1−/− fetal liver cells rescued lethally irradiated recipients and manifested normal long-term repopulating potential in competitive repopulation assays. The recipients of Rce1−/− cells developed modest elevations in mature myeloid cells (neutrophils + monocytes), but remained well. Bone marrow cells from mice that received transplants of Rce1−/− activated extracellular signal-related kinase (ERK) normally in response to granulocyte-macrophage colony-stimulating factor. These data suggest that pharmacologic inhibitors of Rce1 will have minimal effects on normal hematopoietic cells.